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Objectives
After completion of this program, the reader should be able to:
1. Describe the attributes that characterize both the
American Cancer Society (ACS) and U.S. Preventive
Services Task Force (USPSTF) and the major components of each organization.
2. Compare and contrast the methods used by the ACS
and USPSTF when creating cancer screening guidelines.
3. Identify key differences between current ACS and
USPSTF recommendations for breast and prostate
cancer screening.
Abstract
Over the past decades, opportunities for pharmacists to be
actively involved in screening, education and referral for patients have grown. As these opportunities have increased, so
too has the importance of being knowledgeable about the
corresponding recommendations and guidelines. At times,
various expert organizations may publish contradicting
guidelines for a particular disease state or preventive medicine recommendation. This article focuses on the general
background and history of two such expert groups, the
American Cancer Society and the U.S. Preventive Services
Task Force, and compares the two entities’ recommendations
for breast and prostate cancer as of April 2017. It is critical
for pharmacists and pharmacy students to understand these
differences as well as their underlying rationales so as to better advise their patients.
Key Terms
Preventive Health Services; Early Detection of Cancer; Breast
Neoplasms; Prostatic Neoplasms
Introduction
In recent years, there has been a notable shift toward more
patient-centered care in pharmacy practice, allowing pharmacists to establish a more active, clinical role with patients.
Thus, pharmacists must be aware of the availability of pub-

lished guidelines and recommendations that assist health
care professionals in delivering preventive health care interventions.1 Expert organizations regularly update their recommendations as new data becomes available, and various
organizations may publish contradicting guidelines for a particular disease state or preventive medicine recommendation. It is important for health care professionals to be aware
of the discrepancies that exist and the rationale for each so
that they may be better equipped to care for patients.
One such example involves breast and prostate cancer
screening guidelines issued by the American Cancer Society
(ACS) and the U.S. Preventive Services Task Force (USPSTF).
This article will discuss how both the ACS and USPSTF conduct research to formulate their respective guidelines regarding screening for both breast and prostate cancer and
will compare the two entities’ recommendations for breast
and prostate cancer as of April 2017.
The American Cancer Society and the U.S. Preventive
Services Task Force
The ACS is one example of an organization that plays an important role in preventive medicine. The ACS primarily is
concerned with cancer as a health disparity and focuses on
different strategies for cancer prevention and management.
The organization is devoted to conducting research, promoting cancer prevention and educating patients about cancer
with the ultimate goal of eliminating cancer as a major health
problem.2 Specifically, the ACS’s mission statement is to
“save lives, celebrate lives and lead the fight for a world without cancer.”3 The ACS is one of the most prominent groups
today that aids in cancer prevention and management.
In addition to research, the ACS is also responsible for other
aspects of cancer management such as providing support
services and promoting advocacy. Patients can access many
educational materials through the ACS’s website. For support, the ACS provides a telephone hotline number that is
available for patients to call at any time of the day. The phone
number connects patients to cancer specialists with whom
they can speak about a variety of topics such as treatment
options, medications, clinical trials and screenings.4 Lastly,
the ACS strives to work with lawmakers and government
officials in order to pass laws that affect millions of cancer
patients. It has its own nonprofit, nonpartisan advocacy committee known as the American Cancer Society Cancer Action
Network (ACS CAN) which is responsible for promoting
cancer awareness to government policy makers who can
hopefully take actions to make “the fight against cancer a top
national priority.”5,6
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The ACS has issued guidelines for cancer screening since
1980 based on evidence-based medicine principles.7 In 1997,
the methodology underwent a complete revision, and the
ACS protocol developed nine steps to be followed for creating and formalizing guidelines that incorporate the core stages of guideline development, implementation and evaluation.
It was thought that these revisions would create a more formalized approach for deciding which screenings to recommend for all types of cancer. The nine steps are outlined in
Figure 1.7
This formalized method of guideline development led to the
creation of several reliable and effective guidelines; however,
many individuals felt that the process could be further improved in terms of consistency, transparency, scientific rigor
and communications.7 In 2011, the ACS again updated their
process for guideline development following the publication
of guideline standards by the Institute of Medicine (IOM).8
The IOM’s eight principles for guideline development are
summarized in Table 1. The ACS and USPSTF both changed
their process to align with these same principles.9,10
In contrast to the ACS, the USPSTF is, as stated from their
website, an “independent organization consisting of a volunteer panel of national experts” whose purpose is to provide
“recommendations about clinical preventive services such as
screenings, counseling services and preventive medications.”11 The USPSTF’s process for creating guidelines for
preventive services tends to be somewhat more rigorous
than that of the ACS with extra consideration being taken
into how primary care physicians help patients decide
whether or not they should receive screening. The USPSTF’s
mission statement consists of the following two components:
1) “Evaluating the benefits and harms of preventive services

in apparently healthy persons on the basis of age, sex and
known risk factors for disease,” and 2) “Making recommendations about which preventive services should be provided
routinely in primary care practice and which should not.”12
When evaluating a recommendation, the USPSTF categorizes
each of its recommendations into one of five different
“grades” (A, B, C, D or I).13 It is recommended that services
with a grade of A or B be provided to patients. Grade A indicates that there is high certainty that the net benefit of the
service is substantial, while grade B indicates moderate
certainty of moderate-to-substantial net benefit. Services
classified as grade C are recommended based on individual
circumstances. Providing a grade C service to patients should
be based on professional judgment and patient preference, as
there is moderate certainty of a small net benefit. Grade D
indicates that the USPSTF does not recommend the service
due to moderate-to-high certainty that the service either has
no net benefit or the harms outweigh the benefits. Finally,
grade I indicates that current evidence is insufficient to assess benefits versus harms of the service, and patients should
understand the uncertainty of benefit before receiving the
service.
The definitions of each of these grades have undergone several revisions with the most recent revision taking place in
May 2007 and another revision specific to grade C occurring
in July 2012.13 The definitions of each grade correspond to
the level of certainty of the “net benefit” of the recommendation as suggested by the USPSTF. Levels of certainty are
divided into “high,” “moderate” and “low” and are further
described and summarized in Table 2. “Certainty” refers to
the likelihood that the USPSTF’s assessment of the preventive service was correct.

Figure 1. 1997 Update of the American Cancer Society’s Process for Guideline Development.7

14

The Pharmacy And Wellness Review Summer 2017 Volume 8, Issue 3

Breast and Prostate Cancer Screening: Recommendations...

Drug Abuse
Public
Health

Table 1. Institute of Medicine (IOM) Principles for Guideline Development.8
Standards

IOM Recommendations

Transparency

Process and funding of guideline development should be available to the public.

Conflicts of interest

Commercial, institutional, professional and intellectual conflicts of interest must be openly
declared.

Group composition

Multidisciplinary methodological experts, clinicians and patient advocates should be included.

Systematic review
of evidence

Guidelines should be based on a systematic literature review that meets standards set by the IOM.

Grading strength
of recommendations

Explanation of evidence and reasoning, explanation of benefits and harms and indication of level of
confidence in recommendation should be present.

Articulation
of recommendations

Recommendations should be clearly stated and actionable.

External review
Updating

Draft guidelines should be posted for public comment.
Guidelines should be updated when new evidence could result in modifying the recommendations.

With each of these grades, it should be noted that a strong
emphasis is placed on the balance established between the
benefits and harms of the preventive service.13 For example,
if there seem to be slightly more potential benefits than potential harms, the recommendation to use that service will
most likely receive at least a grade C. This approach to making a recommendation is part of the reason why the definition for grade C has undergone so many revisions. As stated
from their website, the USPSTF’s suggestion for practice
from a grade C recommendation is to “offer or provide this
service for selected patients depending on individual circumstances.”13 A risk-benefit assessment must be conducted, and
the overall decision to undergo a screening should be dependent on an individual patient’s circumstance. Thus, although it is important for clinicians to examine and evaluate
the evidence that either supports or rejects a recommendation, the clinicians must also individualize decision-making

to the specific patient or situation. This consideration of benefits and risks also explains why the USPSTF makes separate
recommendations for different populations, including the
general adult population, pregnant women and children.
Guidelines created by the USPSTF are population-based. Clinicians can utilize an application known as the Electronic
Preventive Services Selector (ePSS) to “identify clinical preventive services that are appropriate for their patients”
given patient demographics.14 The application can be used on
multiple platforms such as iPad, Android, iPhone or Windows to identify appropriate preventive services to be offered to specific patients.
The USPSTF follows four major steps when creating its recommendations. The steps can be summarized as follows:
1) topic nomination; 2) draft and final research plans;

Table 2. U.S. Preventive Services Task Force (USPSTF) Levels of Certainty for Recommendations. 13
Level of Certainty

Description

High

Evidence includes consistent results from well-designed, well-conducted studies.
Future study results are unlikely to affect conclusions.

Moderate

Although evidence is sufficient to determine effects of preventive service on
health outcomes, certainty is affected by multiple factors. Recommendation
could change as more information becomes available.

Low

Evidence is insufficient to determine effects of preventive service on health
outcomes. More information is needed.
Summer 2017 Volume 8, Issue 3 The Pharmacy And Wellness Review
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3) draft evidence review and recommendation statement;
4) final evidence review and recommendation statement.
Further details regarding each step of the process are summarized in Figure 2.15
Unlike the ACS, the USPSTF is devoted to making recommendations on preventive services for a variety of disease states
and not solely for different types of cancer. Both organizations, however, employ the same general approach of using
evidence-based medicine in order to formulate their recommendations. So, what exactly makes the USPSTF different
from the ACS in terms of how it develops its guidelines? One
particular area on which the USPSTF focuses is transparency; the USPSTF places a large emphasis on making it clear to
the public exactly how guidelines are developed and the reasons for development. Specifically, the USPSTF has outlined
eight main standards explicitly stated for “developing trustworthy clinical practice guidelines” which are modeled after
the IOM’s standards for guideline development as described
previously.8,9 While the ACS takes a more targeted approach
to developing their guidelines specifically for cancer, the
USPSTF exemplifies a more broad, wide-scale approach for
guideline creation and focuses on how certain preventive
services benefit the patient as a whole with cancer being just
one of many possible disease states.
Breast Cancer Recommendations
Many different prevention and screening recommendations
are available for breast cancer including information about
BRCA gene testing, MRI screening, mammography and physical exams as well as different recommendations for women
at average risk versus high risk of developing breast cancer.
This article focuses on mammography, clinical breast exam
(CBE) and breast self-examination (BSE) screening recom-

mendations from the ACS and USPSTF for women at average
risk for developing breast cancer.
Breast cancer is relatively common in the United States. One
in every eight women in the United States will develop
breast cancer in her lifetime.16 Breast cancer is the second
leading cause of cancer death in women in the United
States.17 Mortality in developed countries has decreased
over the years; however, it is estimated that 40,290 women
died from breast cancer in the United States in 2015. Risk
factors for developing breast cancer include female gender,
older age and estrogen exposure. Genetics are thought to be
a factor in 5 percent to 10 percent of cases.18 Environmental
exposures such as chest radiation therapy or a personal history of abnormal breast biopsies may also increase the risk
of developing breast cancer.
Both the ACS and USPSTF have developed guidelines which
identify populations that should be screened for breast cancer as well as when and how to screen. Recommendations
are specific for average risk and do not address women at
increased risk. The remainder of the discussion will focus on
recommendations for the average risk woman. Although
both groups make similar recommendations, there are a few
key differences between the guidelines. The most recent ACS
guidelines for women at average risk of developing breast
cancer were updated in 2015.17,19 Per these guidelines, a
woman at average risk of developing breast cancer is roughly defined as one without a personal history of breast cancer,
chest radiotherapy at a young age or a specific gene that is
known to increase the risk of breast cancer such as BRCA.
This update was developed using an interdisciplinary team
that formulated and addressed five key questions by specifying populations, interventions, comparisons, outcomes, tim-

Figure 2. U.S. Preventive Services Task Force (USPSTF) Recommendations Development Process. 15

1. Topic Nomination. Any member
of the public may nominate a topic or
an update to a topic at any time via
the U.S. Preventive Services Task
Force website.

4. Final Evidence Review and
Recommendation Statement.
Final evidence recommendation and
summary are published in a peerreviewed scientific journal.
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2. Draft and Final Research Plans.
Plan includes key questions to be
answered and target populations to
be considered.

3. Draft Evidence Review and
Recommendation Statement.
Researchers gather, review and
analyze evidence on the topic from
studies published in peer-reviewed
scientific journals.
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ing of outcomes and settings (PICOTS) for each question.17
For each recommendation the team used Grades of
Recommendation, Assessment, Development and Evaluation
(GRADE) for assessing the strength of the recommendations.
A GRADE of “strong” suggests that most patients would take
this course of action, and a clinician would recommend it.
“Qualified” suggests the majority of patients would take this
course of action, but a risk-benefit analysis may need to be
conducted, so clinicians should take the time to discuss options with patients. The evidence used in creating the guidelines consisted of randomized controlled trials, prospective
or retrospective cohort studies, case-control or cross sectional studies published in 2000 or later that included 1,000 or
more average-risk women, and modeling or simulation studies that allow long-term outcome estimates.
Some of the key questions encompassed the risks and benefits of mammography screening for women of different
ages.17 The ACS guidelines recommend that women with average risk of breast cancer should have the opportunity to
start annual screening between the ages of 40 and 44 years
(qualified). Women should start mammography screening at
the age of 45 years (strong), and continue to be screened
annually from the age of 45 to 54 years (qualified). Women
55 years of age and older should be screened annually or
biennially (qualified). The guidelines also state that a woman
should continue to receive mammograms as long as her overall health is good and her life expectancy is 10 years or more.
The ACS did not specify criteria for good health and left the
decision to continue screening beyond the age of 74 years up
to the provider’s clinical judgment and the patient’s preferences.
In order to determine when to start breast cancer screening,
ACS researchers evaluated the five year absolute risk of developing breast cancer for different age groups.17 They found
that the 45 to 49 years of age group had similar risk (0.9 percent) to the 50 to 54 years of age group (1.1 percent), while
the 40 to 44 years of age group had lower risk (0.6 percent).
Considering the incidence of breast cancer among these
groups and the cancer deaths by age at diagnosis, significant
differences in terms of mortality benefit of mammography
screening and the number of false positives were found between the 40 to 44 years of age group and 45 to 54 years of
age groups. Many randomized controlled trials look at 10year age groups such as 40 to 49 years of age or 50 to 59
years of age and therefore miss some of the differences within those groups. The ACS assessed observational studies in
creating these guidelines as well. While observational studies
do not provide evidence as strong as randomized controlled
trials, these trials found differences between specified ages,
most notably between the 40 to 45 years of age group and 45
to 49 years of age group.20 In a study by Hellquist et al., the
researchers observed an 18 percent reduction in mortality
for the 40 to 45 years of age group and a 32 percent reduction in the 45 to 49 years of age group with mammography
screening. While there are similar false positive findings
among women at age 40 years and women at age 50 years,
the risk of a false positive mammogram increases when the
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screening begins at a younger age due to more screenings
over a lifetime.17 False positives were defined as “recall for
additional testing (imaging and/or biopsy) after abnormal
CBE or mammography in which further evaluation determines that the initial abnormal finding was not cancer.”
When deciding what time interval to recommend for breast
cancer screening, the ACS did not evaluate direct evidence
and, rather, relied heavily on observational studies, mathematical models and simulations.17 Trials have shown that no
benefit in mortality was observed unless the screening interval was less than 24 months. While annual screening significantly reduces mortality, it is also associated with increased
rates of false positives compared to biennial screening. Biennial screening maintains mortality benefit and has been
shown to cut the number of false positives in half compared
to annual screenings.21 In an observational study, White et al.
found that there were better outcomes when women from
the age of 40 to 49 years had annual screens.22 This benefit
was not seen in women who were 50 years of age or older.
Although no randomized controlled trials have included
women aged 75 years or older, modeling and observational
studies have shown a reduction in breast cancer mortality
related to mammography.17 This evidence contributed to the
ACS’s decision to not define a specific age limit for mammography screening and, rather, define the limit as 10 years or
more life expectancy.
The last recommendation in the updated ACS guidelines
states that CBE should not be used at any age, as evidence
shows that there is a lack of benefit compared to mammography.17,19 The ACS also states that there is not enough evidence to make a recommendation on routine BSE, which is
similar to the 2003 guidelines.
The USPSTF developed guidelines in 2002 for screening
women at average risk of breast cancer. Similar to the ACS’s
definition, the USPSTF defines “average risk” as a person who
is not at increased risk for breast cancer due to an underlying
genetic mutation, a history of breast cancer or a history of
chest radiation.18 The USPSTF released a brief update with
recommendations in 2009 and 2015.18,22,23 The 2009 guidelines included evidence from randomized controlled trials,
systematic reviews and meta-analyses. These guidelines excluded any trial that did not include mortality as an outcome.
The USPSTF used the grading system discussed above in order to classify recommendations.12
The most recent update of the USPSTF’s breast cancer
screening guidelines recommends that biennial mammography screening be started at age 50 years and continue until
age 74 years (grade B).23 The USPSTF recommends that
starting biennial screening before age 50 should be an individual decision, and screening could begin between the ages
of 40 and 49 years (grade C). The guidelines also state that
there is insufficient evidence to recommend screening in
women 75 years of age and older (grade I). The USPSTF recommends against teaching women BSE methods (grade D)
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and suggests there is insufficient evidence to make a recommendation for or against CBE beyond 40 years of age (grade I).
The USPSTF concludes that the benefit of biennial screening
from age 50 to 74 years is moderate.1 The mortality benefits
increase with age, while the risks associated with screening,
such as false positives or detection and treatment of noninvasive cancer, are steady and can decrease with age. The
USPSTF suggests the best benefit of screening for breast cancer is achieved for women in their 60s. For women in their
40s, the benefits of screening may outweigh risks; however,
the benefit is small. This is why the USPSTF states that
screening before age 50 years should be an individual choice.
The USPSTF analyzed evidence that suggested benefit was
seen if screening was performed every 12 to 33 months. 23
The USPSTF recommends biennial screening because they
determined this was likely to have the highest benefit in
terms of fewer false positives or other harms, while still
maintaining mortality benefit.
Currently, there are no trials comparing CBE without mammography or CBE with mammography compared to mammography alone and, therefore, the USPSTF says that there is
not sufficient evidence to make recommendations for or
against CBE in the United States (grade I).18 Trials conducted
outside of the United States in regard to teaching women
BSE did not show mortality benefit.24 These trials did illustrate that women may be more likely to have unnecessary
biopsies or additional screening done if they performed BSE.
Therefore, the USPSTF chose to recommend against teaching
women BSE (grade D).18
Table 3 highlights some of the differences in breast cancer
recommendations between the ACS and USPSTF.17,23 These
differences may stem from how each organization collects
and evaluates evidence. For example, the ACS included observational studies that showed a difference between the 40
to 44 years of age group and 45 to 50 years of age group,
whereas the USPSTF used randomized controlled trials and
other evidence that focused on the 10 year age differences.
The ACS is also much more focused on the clinical picture of

the patients and takes things such as cost of therapies and
the patient’s emotional and physical well-being into consideration in addition to the evidence. The USPSTF, on the other
hand, is driven more by evidence, as stated in their guidelines, and does not take into consideration the cost of screening.17,18
Prostate Cancer Recommendations
Prostate cancer is the most common cancer found in men
other than skin cancer in the United States.27 While prostate
cancer can be a serious disease, most men diagnosed will not
die from it. The ACS and USPSTF both have developed guidelines for men regarding prostate cancer screening.
The ACS uses two specific aims to determine its recommendations: recommendations to providers and patients for
screening of average-risk men and recommendations for
screening higher-risk men, principally African American men
and men with at least one first-degree relative with prostate
cancer.25 These two aims form a recommendation that is
most appropriate for each patient population regarding
screening tests and frequency of testing that incorporates
the patient into the health care decision process.
The ACS guideline for prostate cancer incorporates men into
the decision of whether to initiate and continue testing for
prostate cancer throughout their life by encouraging patient
communication with health care providers.25 This requires
men to have basic background knowledge about prostate
cancer. The ACS encourages providers and patients to use
screening decision aids to facilitate the process beginning at
age 50 years for men with average risk. It is recommended
that men with a life expectancy of at least 10 years have an
opportunity to make an informed decision about prostate
cancer screening. For men at a higher risk, it is recommended that they be provided with the opportunity for an informed decision about screening before the age of 50
years.25
When developing guidelines, the ACS looked at two prospective randomized trials: the European Randomized Study of

Table 3. Differences in Breast Cancer Screening Recommendations from the American Cancer Society (ACS) and the
U.S. Preventive Services Task Force (USPSTF).17,18,23
Screening Parameter

ACS Recommendation

USPSTF Recommendation

Age to initiate mammography screening

45 years, give opportunity at 40
years

50 years, may consider for
40 to 49 years

Interval of mammography screening

Annually until age 55 years, then
biennially or annually

Biennially

Age to cease mammography screening

None specified, should have a life
expectancy of 10 or more years

Not enough evidence for
screening beyond 75 years

Clinical breast exam (CBE) recommendation

Not recommended

Insufficient evidence

Breast self-examination (BSE) recommendation

Insufficient evidence

Not recommended
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Screening for Prostate Cancer (ERSPC) and the prostate arm
of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer
Screening Trial in the United States. The ERSPC and PLCO
results did not show a reduction in mortality with screening.25 While the benefits of prostate cancer screening are uncertain, the problems associated with screening are known.
It has been estimated that 23 percent to 42 percent of cancers detected through screening would not have been identified in the absence of screening. This reflects the potential for
overdiagnosis, the diagnosis of a disease that will never
cause symptoms or death during the patient's expected lifetime, and unnecessary treatment of a disease. It is not possible to predict which men are likely to benefit from treatment
of prostate cancer if the cancer is detected through screening. Treatment for prostate cancer can also include many
adverse effects such as sexual, urinary and bowel-related
complications that could be potentially life-altering.
Evidence shows that periodic testing of prostate-specific antigen (PSA) levels may reduce the likelihood of dying from
prostate cancer.25 However, this must be weighed against the
risk incurred from early detection and subsequent treatment,
especially in those who would not have experienced effects
from the cancer if it had been left undetected. One of the
highest reported harms associated with PSA screening is
anxiety relating to receiving a positive PSA result, a positive
biopsy or a false positive PSA result. Those who receive positive results may also experience adverse or harmful effects
from other treatment options such as radiation therapy, hormone replacement therapy and recurrent biopsies.
The ACS concludes that men should be involved in the decision of whether or not to begin prostate cancer screening
during their lifetime.25 Men are encouraged to discuss the
importance, potential benefits and risks of various prostate
screening options with their providers. If a man decides to
undergo prostate cancer screening, the ACS offers the following guidance: the traditional PSA level of 4 ng/mL or greater
is considered reasonable to warrant further evaluation; however, it should be acknowledged that there is no true PSA
value that distinguishes cancer from noncancer. It is suggested that providers consider the patient individually when
making a decision about PSA levels that fall between 2.5 ng/
mL and 4 ng/mL, especially in men who have an increased
risk for prostate cancer based on nonPSA risk factors. The
ACS further recommends that the time between future
screenings should be based on the results of the PSA blood
test. Patients with PSA levels less than 2.5 ng/mL may only
need to be retested every two years, while screening should
be done yearly for patients with PSA levels of 2.5 ng/mL or
higher.
In contrast to the ACS, the USPSTF currently classifies prostate cancer screening as a grade D recommendation, meaning
that the USPSTF recommends against performing prostate
screenings.26 From their research, the USPSTF concluded that
evidence illustrates with moderate to high certainty that
screening has no benefit or that the harms of screening outweigh the benefits. Past studies have found only a small re-
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duction in prostate cancer mortality after 10 to 14 years,
thus demonstrating that the benefits of PSA-based screening
for prostate cancer do not outweigh the harms.
When determining guidelines, the USPSTF considered the
prognosis of prostate cancer.26 A man living in the United
States has a 15.9 percent risk of being diagnosed with prostate cancer during his lifetime. The current lifetime risk of
dying as a result of prostate cancer is 2.8 percent, and 70
percent of deaths occur after the age of 75 years. A majority
of cases have good prognosis, even without treatment. Furthermore, prostate cancer is rare in men younger than 50
years of age.
Detection of prostate cancer is most commonly done by
measuring serum PSA levels. The PSA screening detects
asymptomatic cancer in a substantial amount of men, leading
to unnecessary treatment as in many cases the tumor would
not have progressed or would progress slowly enough such
that the patient would remain asymptomatic for his entire
life. The rate of overdiagnosis of prostate cancer leading to
unnecessary treatment ranges from 17 percent to 50 percent. 26 The rate of overdiagnosis depends on the life expectancy of the patient, any chronic disease states present that
would shorten the patient’s life span and the number of biopsies taken. As the number of biopsies taken increases, the
rate of overdiagnosis increases.
With the risk of over-diagnosis, the USPSTF considered the
benefits of early treatment versus the harms when determining their screening recommendations.26 The primary goal of
screening is to reduce the deaths due to the disease and increase the length of life by reducing the development of
symptomatic, metastatic disease. Men who have prostate
cancer fall into one of three categories: those whose cancer
will result in death despite early diagnosis and treatment,
those who will have good outcomes in the absence of screening and those for whom early diagnosis and treatment improve survival. Like the ACS, the USPSTF also looked at the
PLCO and ERSPC trials when developing their guideline recommendations. Results from the PLCO trial did not show a
reduction in prostate cancer mortality, while the ERSPC trial
found a reduction in prostate cancer deaths of approximately
one death per 1,000 men. The European trial found this reduction in a subgroup of men aged 55 to 69 years in two out
of the seven countries included in the study. Statistically significant reduction in mortality was not seen in the other five
countries included in the ERSPC trial.
The USPSTF concluded that the benefit of PSA screening and
early treatment is minimal with prevention of only zero to
one prostate cancer deaths per 1,000 men screened.26 Due to
the minimal benefits seen, the USPSTF also examined the
harms related to PSA screening and diagnostic procedures.
The PSA tests often produce false positive results (approx.imately 80 percent) which are associated with negative psychological effects such as constant worry about prostate cancer. False positives also necessitate additional testing which
may be accompanied by pain, fever and bleeding. The
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Table 4. Differences in Prostate-Specific Antigen (PSA) Screening Recommendations from the American Cancer Society (ACS) and the U.S. Preventive Services Task Force (USPSTF).25-27

Screening Parameter

ACS Recommendation

Age to initiate PSA screening

50 years of age if average risk
45 years of age if high risk
40 years of age if have more than one
first-degree relative with early-age prostate
cancer

Not recommended

Interval of PSA screening

Yearly if result greater than 2.5 ng/mL

Not recommended

Age to cease PSA screening

None specified; should have a life
expectancy of 10 or more years

Not recommended

PSA level recommendation

>4.0 ng/mL reason for further evaluation

Not recommended

USPSTF considered the magnitude of the harms associated
with PSA screening as small but influential on the patient’s
daily life.
Evidence shows that almost 90 percent of men with PSAdetected prostate cancer in the United States undergo early
treatment including surgery, radiation or androgen deprivation therapy.26 Of these men, five out of 100 will die within
one month of surgery, and between 10 to 70 men will have
serious complications posttreatment but will survive. The
evidence that PSA screening leads to overdiagnosis of prostate tumors is of major concern because a man would have
remained asymptomatic for the remainder of his life even if
he had not been diagnosed with the cancer. Men are therefore being subjected to the harms of treatment for a much
longer period of time. As a result, the USPSTF recommends
against prostate cancer screening. Table 4 outlines some of
the differences in prostate cancer screening recommendations from the USPSTF compared to recommendations from
the ACS.
Conclusion
The ACS and USPSTF are organizations that strive to produce evidence-based recommendations for preventive services that are applicable to the general population as well as
specific patient populations. Often, differences in each organization’s process for research and evaluation of evidence
lead to varying conclusions for guideline recommendations.
For breast cancer screening, the ACS and USPSTF make similar recommendations with a few key differences regarding
the age to initiate mammography screenings, the age to
cease mammography screenings and the interval for mammography screening. For prostate cancer detection, the ACS
and USPSTF recommendations differ regarding whether PSA
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screening should be performed or not. When offering
screening for the early detection of various diseases, it is
important that pharmacists and other health care providers
review the recommendations published by various groups.
In order to appropriately care for patients, health care professionals should understand any discrepancies between the
various recommendations and how each organization
reached its conclusions so that they may use their clinical
judgment to make the best possible decisions for the early
detection of disease.
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Assessment Questions
1.

What is the American Cancer Society (ACS) recommended interval of screening for breast cancer in women ages
45 to 50 years?
A. Every 24 months
B. Every 12 months
C. Every 6 months
D. Every 36 months

2.

Which of these is true regarding breast cancer screening?
A. Clinical breast examination (CBE) is recommended by both the ACS and the U.S. Preventive
Services Task Force (USPSTF).
B. If mammography screening is initiated at the
age of 40 years compared to the age of 50 years,
there is increased incidence of false positive test
results.
C. The ACS recommends that women start screening at the age of 50 years, and the USPSTF recommends that women start screening at the age
of 45 years.
D. Breast self-examination (BSE) technique should
be taught to all women starting at the age of 18
years.

3.

Which organization classifies its recommendations
based on a “grading” scale (A-I) and organizes its level of
certainty of the evidence as “high,” “medium” or “low”?
A. ACS
B. USPSTF

4.

Both the ACS and the USPSTF try to model their guidelines in line with the standards of which organization?
A. Institute of Medicine
B. The Joint Commission
C. National Academy of Sciences
D. American Hospital Association

5.

Which organization, in addition to research, deals with
other aspects of cancer management such as providing
patient support services, encouraging prevention and
promoting advocacy?
A. ACS
B. USPSTF

6.
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At what age does the ACS recommend to start screening
for prostate cancer for the average man?
A. 40 years of age
B. 45 years of age
C. 50 years of age
D. The ACS does not recommend screening.

7.

At what age does the USPSTF recommend to begin prostate screening for the average man?
A. 40 years of age
B. 45 years of age
C. 50 years of age
D. The USPSTF does not recommend screening.

8.

According to the ACS, it is recommended that men who
have a life expectancy of at least 10 years have an
opportunity to make an informed decision about
prostate cancer screening.
A. True
B. False

9.

Which patient would be considered to be at average risk
of developing breast cancer according to the ACS?
A. 42-year-old female with no personal or family
history of breast cancer
B. 79-year-old female currently in remission who
was treated for breast cancer at the age of 50
years
C. 23-year-old female known to have the BRCA
gene

10. Which of the following statements is correct based on
the ACS guidelines for breast cancer screening?
A. Women should stop mammography screening at
the age of 75 years due to lack of evidence for
benefit.
B. Women should continue to be screened with
mammography as long as they are in good
health and have a life expectancy of at least 10
years.
C. Women should start biennial screening mammography at the age of 40 years.
D. None of the above.
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